We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
+31.58%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$250M
AUM Growth
+$80.2M
Cap. Flow
+$54.1M
Cap. Flow %
21.67%
Top 10 Hldgs %
36.89%
Holding
128
New
62
Increased
6
Reduced
21
Closed
36

Top Buys

Rank Stock Value
1
INSP icon
Inspire Medical Systems
INSP
+$6.46M
2
HOLX
Hologic
HOLX
+$3.37M
3
SYNH
Syneos Health, Inc. Class A Common Stock
SYNH
+$2.9M
4
STAA icon
STAAR Surgical
STAA
+$2.34M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$2.33M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$4.14M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$4.09M
3
ABT icon
Abbott
ABT
+$3.63M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$3.54M
5
GMED icon
Globus Medical
GMED
+$3.52M

Sector Composition

Rank Sector Weight
1 Healthcare 37.06%
2 Industrials 1.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XENE icon
76
Xenon Pharmaceuticals
XENE
$6.14B
$690K 0.28%
+75,000
New +$466K
GERN icon
77
PUT
Geron
GERN
$1.02B
$686K 0.27%
+200,000
New +$764K
INCY icon
78
CALL
Incyte
INCY
$24.5B
$670K 0.27%
10,000
-10,000
-50% -$684K
TGTX icon
79
TG Therapeutics
TGTX
$7.66B
$658K 0.26%
50,000
– –
XNCR icon
80
Xencor
XNCR
$1.64B
$555K 0.22%
+15,000
New +$517K
STAA icon
81
CALL
STAAR Surgical
STAA
$1.25B
$543K 0.22%
+17,500
New +$409K
EIGR
82
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$488K 0.2%
+1,333
New +$475K
CPRX
83
DELISTED
Catalyst Pharmaceutical
CPRX
$468K 0.19%
+150,000
New +$455K
GBT
84
CALL
DELISTED
Global Blood Therapeutics, Inc.
GBT
$466K 0.19%
+10,300
New +$469K
VKTX icon
85
Viking Therapeutics
VKTX
$3.96B
$447K 0.18%
47,100
-127,770
-73% -$850K
ITCI
86
CALL
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$442K 0.18%
+25,000
New +$508K
ZVRA icon
87
Zevra Therapeutics
ZVRA
$675M
$390K 0.16%
+3,750
New +$366K
ARDX icon
88
Ardelyx
ARDX
$997M
$370K 0.15%
+100,000
New +$464K
ITCI
89
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$353K 0.14%
+20,000
New +$406K
OTIC
90
DELISTED
Otonomy, Inc.
OTIC
$319K 0.13%
82,794
-69,692
-46% -$290K
CYTK icon
91
CALL
Cytokinetics
CYTK
$10.8B
$204K 0.08%
+24,600
New +$205K
FOMX
92
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$121K 0.05%
24,100
– –
ABT icon
93
Abbott
ABT
$190B
– –
-60,500
Closed -$3.63M
AMGN icon
94
CALL
Amgen
AMGN
$224B
– –
-10,000
Closed -$1.71M
ARAY icon
95
Accuray
ARAY
$36.1M
– –
-88,958
Closed -$412K
BMRN icon
96
BioMarin Pharmaceuticals
BMRN
$13.4B
– –
-43,700
Closed -$3.54M
BMY icon
97
CALL
Bristol-Myers Squibb
BMY
$130B
– –
-100,000
Closed -$6.33M
CHRS icon
98
CALL
Coherus Oncology
CHRS
$188M
– –
-50,000
Closed -$553K
CI icon
99
CALL
Cigna
CI
$72.1B
– –
-35,000
Closed -$5.87M
CLSD
100
DELISTED
Clearside Biomedical
CLSD
– –
-4,507
Closed -$725K
2 3
4
5 6

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return
M
MetLife New York $12.3M AUM 29% 1-Year Est. Return

Pura Vida Investments's Q2 2018 Portfolio in Review

As of Q2 2018, Pura Vida Investments held 128 positions worth $250M, up 47% from $169M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Pura Vida Investments deployed $54.1M of net new capital in Q2 2018, opening 62 new positions and adding to 6 existing holdings. Its largest new stake was Inspire Medical Systems: 200,280 shares worth $7.14M.

By sector, the portfolio is most concentrated in Healthcare at 37% of assets, down from 52% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was Merck, an estimated $4.14M trimmed.

  • Pura Vida Investments's largest Q2 2018 buy was Inspire Medical Systems: 200,280 shares worth $7.14M.
  • Pura Vida Investments added most to Allergan plc in Q2 2018, an estimated $1.61M increase.
  • Pura Vida Investments's biggest Q2 2018 reduction was Merck, cutting an estimated $4.14M.
  • Pura Vida Investments fully exited Abbott in Q2 2018, selling an estimated $3.63M.
  • Pura Vida Investments's ten largest holdings make up 37% of its $250M portfolio in Q2 2018.
  • Pura Vida Investments opened 62 new positions and closed 36 in Q2 2018.
  • Pura Vida Investments's portfolio value rose 47% quarter-over-quarter to $250M.

Based on Pura Vida Investments's 13F filing for Q2 2018, filed 14 Aug 2018.